INTUITIVE INVESTMENTS GROUP PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 130 GBX | -.--% |
|
+1.96% | -5.45% |
| Feb. 27 | Intuitive Investments investee gets approval for China PELT expansion | AN |
| Jan. 31 | EARNINGS: BSF Enterprise "making great strides", Sylvania ups earnings | AN |
| Sales 2022 | -1.24M -1.55M | Sales 2023 | -2.44M -3.05M | Capitalization | 7.17M 8.95M |
|---|---|---|---|---|---|
| Net income 2022 | -1M -1.25M | Net income 2023 | -3M -3.75M | EV / Sales 2022 | -3.39 x |
| Net cash position 2022 | 1.55M 1.94M | Net cash position 2023 | 1.74M 2.17M | EV / Sales 2023 | -2.22 x |
| P/E ratio 2022 |
-4.35
x | P/E ratio 2023 |
-1.91
x | Employees | 5 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 26.09% |
More Fundamentals
* Assessed data
More news
| 1 week | +1.96% | ||
| Current month | -8.77% | ||
| 1 month | -8.77% | ||
| 3 months | +30.00% | ||
| 6 months | +18.18% | ||
| Current year | -5.45% |
1 week
125.00
132.50
1 month
115.00150.00
Current year
95.00150.00
1 year
40.00156.00
3 years
40.00242.00
5 years
40.00280.00
10 years
40.00280.00
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Naylor
CEO | Chief Executive Officer | 50 | 20-12-07 |
| Director of Finance/CFO | 55 | - | |
Giles Willits
CIO | Chief Investment Officer | 57 | Nov. 27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Rudd
CHM | Chairman | 76 | 23-08-07 |
Malcolm Gillies
BRD | Director/Board Member | 74 | 20-06-10 |
Colin Willis
BRD | Director/Board Member | 57 | 20-12-13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 130 | -.--% | 57,514 |
| 24-04-29 | 130 | -.--% | 7,013 |
| 24-04-26 | 130 | -.--% | 4,646 |
| 24-04-25 | 130 | -.--% | 26,945 |
| 24-04-24 | 130 | -.--% | 6,346 |
Delayed Quote London S.E., April 30, 2024 at 11:35 am EDT
More quotes
Intuitive Investments Group plc is a United Kingdom-based closed-end investment company, which is focused on the life sciences sector. The Companyâs investment objective is to generate capital growth over the long term through investment in a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the United Kingdom, continental Europe, and the United States. The Company invests in early and late-stage life sciences businesses. It invests in the form of equity and equity-related instruments, including convertible debt instruments. The Company may acquire investments directly or by way of holdings in intermediate holding or subsidiary entities. The Company categories investment opportunities into sub-sectors in life sciences, such as diagnostics and healthcare, medical devices, tools and technologies, biotherapeutics and pharmaceuticals. Its adviser is SP Angel Corporate Finance LLP.
Sector
Closed End Funds
Calendar
2024-05-28
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -5.45% | 330M | |
| +2.90% | 12.63B | |
| +6.03% | 9.1B | |
| -4.26% | 5.38B | |
| +4.00% | 5.36B | |
| +5.91% | 5.19B | |
| +10.02% | 4.47B | |
| +14.35% | 4.44B | |
| +1.29% | 4B | |
| +3.58% | 3.86B |
- Stock Market
- Equities
- IIG Stock
